Mark T Osterman1, Kevin Haynes2, Elizabeth Delzell3, Jie Zhang3, Meenakshi Bewtra4, Colleen Brensinger5, Lang Chen6, Fenlong Xie6, Jeffrey R Curtis7, James D Lewis8. 1. Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 2. Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Center for Pharmacoepidemiology Research and Teaching, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 3. Department of Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, Alabama. 4. Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 5. Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 6. Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama. 7. Department of Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, Alabama; Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 8. Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Center for Pharmacoepidemiology Research and Teaching, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: lewisjd@mail.med.upenn.edu.
Abstract
BACKGROUND & AIMS: Antibodies against tumor necrosis factor-α are widely used to treat patients with Crohn's disease (CD). This study compared the effectiveness of infliximab and adalimumab, the 2 most commonly used anti-tumor necrosis factor agents, in patients with CD. METHODS: We conducted a retrospective cohort study by using U.S. Medicare data from 2006 through 2010. Patients with CD who were new users of infliximab (n = 1459) or adalimumab (n = 871) after January 31, 2007, were included. Patients older than age 85 and those with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis were excluded. The primary outcome measures were disease persistence on therapy at week 26, surgery (including bowel resection, creation of an ostomy, or surgical treatment of a perforation or abscess), and hospitalization for CD. Propensity score-adjusted logistic and Cox regression were used to compute adjusted odds ratios or hazard ratios and 95% confidence intervals (CIs). RESULTS: After 26 weeks of treatment, 49% of patients receiving infliximab remained on drug, compared with 47% of those receiving adalimumab (odds ratio, 0.98; 95% CI, 0.81-1.19). Fewer patients treated with infliximab underwent surgery than those treated with adalimumab, but this difference was not statistically significant (5.5 vs 6.9 surgeries per 100 person-years; hazard ratio, 0.79; 95% CI, 0.60-1.05). Rates of hospitalization did not differ between groups (hazard ratio, 0.88; 95% CI, 0.72-1.07). CONCLUSIONS: We observed similar effectiveness of infliximab and adalimumab for CD on the basis of 3 clinically important outcome measures.
BACKGROUND & AIMS: Antibodies against tumor necrosis factor-α are widely used to treat patients with Crohn's disease (CD). This study compared the effectiveness of infliximab and adalimumab, the 2 most commonly used anti-tumor necrosis factor agents, in patients with CD. METHODS: We conducted a retrospective cohort study by using U.S. Medicare data from 2006 through 2010. Patients with CD who were new users of infliximab (n = 1459) or adalimumab (n = 871) after January 31, 2007, were included. Patients older than age 85 and those with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis were excluded. The primary outcome measures were disease persistence on therapy at week 26, surgery (including bowel resection, creation of an ostomy, or surgical treatment of a perforation or abscess), and hospitalization for CD. Propensity score-adjusted logistic and Cox regression were used to compute adjusted odds ratios or hazard ratios and 95% confidence intervals (CIs). RESULTS: After 26 weeks of treatment, 49% of patients receiving infliximab remained on drug, compared with 47% of those receiving adalimumab (odds ratio, 0.98; 95% CI, 0.81-1.19). Fewer patients treated with infliximab underwent surgery than those treated with adalimumab, but this difference was not statistically significant (5.5 vs 6.9 surgeries per 100 person-years; hazard ratio, 0.79; 95% CI, 0.60-1.05). Rates of hospitalization did not differ between groups (hazard ratio, 0.88; 95% CI, 0.72-1.07). CONCLUSIONS: We observed similar effectiveness of infliximab and adalimumab for CD on the basis of 3 clinically important outcome measures.
Authors: S T C Peake; J Landy; M Hussein; C T Tee; M O'Connor; T Tyrrell; A Akbar; A L Hart Journal: Inflamm Bowel Dis Date: 2011-05-01 Impact factor: 5.325
Authors: Gert Van Assche; Séverine Vermeire; Vera Ballet; Frederik Gabriels; Maja Noman; Geert D'Haens; Christophe Claessens; Evelien Humblet; Niels Vande Casteele; Ann Gils; Paul Rutgeerts Journal: Gut Date: 2011-09-23 Impact factor: 23.059
Authors: Joseph A Markenson; Allan Gibofsky; William R Palmer; Edward C Keystone; Michael H Schiff; Jingyuan Feng; Scott W Baumgartner Journal: J Rheumatol Date: 2011-05-15 Impact factor: 4.666
Authors: Daniel A Sussman; Nisa Kubiliun; Parvez M Mulani; Jingdong Chao; Carol A T Gillis; Mei Yang; Mei Lu; Maria T Abreu Journal: Inflamm Bowel Dis Date: 2012-01-12 Impact factor: 5.325
Authors: Carlos G Grijalva; Lang Chen; Elizabeth Delzell; John W Baddley; Timothy Beukelman; Kevin L Winthrop; Marie R Griffin; Lisa J Herrinton; Liyan Liu; Rita Ouellet-Hellstrom; Nivedita M Patkar; Daniel H Solomon; James D Lewis; Fenglong Xie; Kenneth G Saag; Jeffrey R Curtis Journal: JAMA Date: 2011-11-06 Impact factor: 56.272
Authors: Jeffrey D Greenberg; George Reed; Dennis Decktor; Leslie Harrold; Daniel Furst; Allan Gibofsky; Ralph Dehoratius; Mitsumasa Kishimoto; Joel M Kremer Journal: Ann Rheum Dis Date: 2012-01-30 Impact factor: 19.103
Authors: Mirthe Emilie van der Valk; Marie-Josée J Mangen; Max Leenders; Gerard Dijkstra; Ad A van Bodegraven; Herma H Fidder; Dirk J de Jong; Marieke Pierik; C Janneke van der Woude; Mariëlle J L Romberg-Camps; Cees H M Clemens; Jeroen M Jansen; Nofel Mahmmod; Paul C van de Meeberg; Andrea E van der Meulen-de Jong; Cyriel Y Ponsioen; Clemens J M Bolwerk; J Reinoud Vermeijden; Peter D Siersema; Martijn G H van Oijen; Bas Oldenburg Journal: Gut Date: 2012-11-07 Impact factor: 23.059
Authors: Mark T Osterman; Kevin Haynes; Elizabeth Delzell; Jie Zhang; Meenakshi Bewtra; Colleen M Brensinger; Lang Chen; Fenglong Xie; Jeffrey R Curtis; James D Lewis Journal: Clin Gastroenterol Hepatol Date: 2015-02-24 Impact factor: 11.382
Authors: Frank I Scott; Ronac Mamtani; Colleen M Brensinger; Kevin Haynes; Zelma C Chiesa-Fuxench; Jie Zhang; Lang Chen; Fenglong Xie; Huifeng Yun; Mark T Osterman; Timothy Beukelman; David J Margolis; Jeffrey R Curtis; James D Lewis Journal: JAMA Dermatol Date: 2016-02 Impact factor: 10.282
Authors: K T Park; Wallace V Crandall; Jacqueline Fridge; Ian H Leibowitz; Marc Tsou; Dana M H Dykes; Edward J Hoffenberg; Michael D Kappelman; Richard B Colletti Journal: Inflamm Bowel Dis Date: 2014-05 Impact factor: 5.325
Authors: Siddharth Singh; Herbert C Heien; Lindsey R Sangaralingham; Stephanie R Schilz; Michael D Kappelman; Nilay D Shah; Edward V Loftus Journal: Clin Gastroenterol Hepatol Date: 2016-04-04 Impact factor: 11.382
Authors: Ronac Mamtani; Amy S Clark; Frank I Scott; Colleen M Brensinger; Ben Boursi; Lang Chen; Fenglong Xie; Huifeng Yun; Mark T Osterman; Jeffrey R Curtis; James D Lewis Journal: Arthritis Rheumatol Date: 2016-10 Impact factor: 10.995
Authors: R W Stidham; T C H Lee; P D R Higgins; A R Deshpande; D A Sussman; A G Singal; B J Elmunzer; S D Saini; S Vijan; A K Waljee Journal: Aliment Pharmacol Ther Date: 2014-04-20 Impact factor: 8.171
Authors: S Singh; H C Heien; L R Sangaralingham; S R Schilz; M D Kappelman; N D Shah; E V Loftus Journal: Aliment Pharmacol Ther Date: 2016-03-15 Impact factor: 8.171